Literature DB >> 9393

Phosphofructokinase. I. Mechanism of the pH-dependent inactivation and reactivation of the rabbit muscle enzyme.

P E Bock, C Frieden.   

Abstract

The kinetics of inactivation and reactivation of rabbit skeletal muscle phosphofructokinase have been studied as a function of pH and enzyme concentration at constant temperature in phosphate buffer. From the enzyme concentration dependence, we conclude that the minimal mechanism for inactivation involves a protonation step followed by isomerization to an inactive form and then dissociation to a species of one-half the molecular weight. Other data indicate a subsequent isomerization of the dissociated form. The pH and temperature dependence of the inactivation process shows that it is controlled by ionizable groups, and that the apparent pK for these groups is temperature-dependent in such a way as to make the enzyme show the characteristic of cold lability below pH 7. Reactivation of the inactive enzyme occurs by a kinetically different pathway involving deprotonation of an inactive, dissociated form to a form which may either isomerize to another inactive form, or dimerize to the active enzyme. A general mechanism is postulated in which the inactivation and reactivation processes are different aspects of the same mechanism. This mechanism assumes four species (two containing four subunits and two containing two subunits) each of which can exist in a protonated and unprotonated form. Inactivation or reactivation induced by changes in pH or temperature reflect the kinetic establishment of a new steady state between these forms. How the apparent pK values which control the distribution of the enzyme between protonated and unprotonated forms describe the pH-dependent characteristics of the enzyme is discussed in terms of the proposed mechanism.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 9393

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Shape of phosphofructokinase from Escherichia coli in solution.

Authors:  H H Paradies; W Vettermann; G Werz
Journal:  Protoplasma       Date:  1977       Impact factor: 3.356

Review 2.  Preimplantation stress and development.

Authors:  Sky Feuer; Paolo Rinaudo
Journal:  Birth Defects Res C Embryo Today       Date:  2012-12

3.  Reassessment of the cold-labile nature of phosphofructokinase from a hibernating ground squirrel.

Authors:  J A MacDonald; K B Storey
Journal:  Mol Cell Biochem       Date:  2001-09       Impact factor: 3.396

Review 4.  Allosteric regulatory properties of muscle phosphofructokinase.

Authors:  R G Kemp; L G Foe
Journal:  Mol Cell Biochem       Date:  1983       Impact factor: 3.396

5.  Permeabilization of animal cells for kinetic studies of intracellular enzymes: in situ behavior of the glycolytic enzymes of erythrocytes.

Authors:  J J Aragón; J E Felíu; R A Frenkel; A Sols
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

6.  Circulatory and metabolic responses of malignant tumors during localized hyperthermia.

Authors:  P Vaupel; K Ostheimer; W Müller-Klieser
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

7.  Obfuscation of allosteric structure-function relationships by enthalpy-entropy compensation.

Authors:  V L Tlapak-Simmons; G D Reinhart
Journal:  Biophys J       Date:  1998-08       Impact factor: 4.033

8.  Oxygen tensions in multicell spheroids of two cell lines.

Authors:  W F Mueller-Klieser; R M Sutherland
Journal:  Br J Cancer       Date:  1982-02       Impact factor: 7.640

9.  Cytostatic potential of novel agents that inhibit the regulation of intracellular pH.

Authors:  P Wong; H-W Kleemann; I F Tannock
Journal:  Br J Cancer       Date:  2002-07-15       Impact factor: 7.640

10.  Anti-cancer strategy targeting the energy metabolism of tumor cells surviving a low-nutrient acidic microenvironment.

Authors:  Yuki Maeda; Ryota Kikuchi; Junichiro Kawagoe; Takao Tsuji; Nobuyuki Koyama; Kazuhiro Yamaguchi; Hiroyuki Nakamura; Kazutetsu Aoshiba
Journal:  Mol Metab       Date:  2020-09-30       Impact factor: 7.422

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.